BioMarin Pharmaceutical (BMRN) : The short interest in BioMarin Pharmaceutical (BMRN) has changed with an increase of 1,086,500 shares and the open interest is 17.7%. From 6,139,756 short positions on Jul 29, 2016, the shorts increased to 7,226,256 shares by August 15, 2016. There are 4 more days left for the expiry and the daily trading volume of the stock is 2,056,060 shares. The total interest of shorts is 4.5% of the shares available to the public. The short interest information was released on Wednesday Aug 24th after the market close.
BioMarin Pharmaceutical (NASDAQ:BMRN): The stock opened at $99.22 on Wednesday but the bulls could not build on the opening and the stock topped out at $102.06 for the day. The stock traded down to $94.50 during the day, due to lack of any buying support eventually closed down at $95.13 with a loss of -4.32% for the day. The stock had closed at $99.43 on the previous day. The total traded volume was 2,482,525 shares.
In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director officer (Chief Executive Officer) of Biomarin Pharmaceutical Inc, Bienaime Jean Jacques had sold 41,666 shares worth of $3,812,022 in a transaction dated August 16, 2016. In this transaction, 41,666 shares were sold at $91.49 per share.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Companys product portfolio is comprised of five approved products and multiple clinical and pre-clinical product candidates. Its approved products are Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States, the European Union and subsequently in several other countries. Naglazyme received marketing approval in the United States, the European Union and subsequently in other countries. Kuvan was granted marketing approval in the United States, the European Union. Aldurazyme, which was developed in collaboration with Genzyme Corporation (Genzyme), was approved for marketing in the United States, the European Union, and subsequently in other countries. Firdapse was approved by the European Medicines Agency (EMA).